Credit Industriel ET Commercial Acquires New Position in Inhibrx, Inc. (NASDAQ:INBX)

Credit Industriel ET Commercial bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 64,217 shares of the company's stock, valued at approximately $989,000. Credit Industriel ET Commercial owned about 0.44% of Inhibrx at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. HighTower Advisors LLC purchased a new position in shares of Inhibrx during the 4th quarter valued at approximately $12,039,000. Walleye Capital LLC purchased a new stake in shares of Inhibrx during the 4th quarter worth about $8,932,000. Slotnik Capital LLC acquired a new stake in shares of Inhibrx during the 4th quarter valued at about $5,975,000. Geode Capital Management LLC purchased a new position in shares of Inhibrx in the 4th quarter valued at about $3,930,000. Finally, Kennedy Capital Management LLC acquired a new position in Inhibrx in the 4th quarter worth about $2,551,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Stock Performance

NASDAQ:INBX traded down $0.56 during trading hours on Tuesday, reaching $11.80. 168,282 shares of the company were exchanged, compared to its average volume of 197,372. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $34.75. The stock's 50-day moving average is $13.00 and its 200-day moving average is $14.03.

Inhibrx (NASDAQ:INBX - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. As a group, research analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.